Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Annovis Bio, Inc.

Get SEC filing alerts via email and in your feed for Annovis Bio, Inc.

ANVS

Annovis Bio, Inc.

About Annovis Bio, Inc.

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative diseases, primarily Alzheimer’s and Parkinson’s. Its lead product candidate, buntanetap, is an oral small molecule designed to inhibit multiple neurotoxic proteins involved in disease progression, aiming to improve cognition and motor function. Annovis targets large aging populations with unmet medical needs through a drug development platform focused on disease-modifying treatments for chronic and acute neurodegeneration.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Annovis Bio, Inc.

1
1
Annovis Bio, Inc. Annovis Bio Reports Increased Net Loss of $17.6 Million in Q1 2026

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Annovis Bio, Inc. Annovis Bio Reports Q3 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
Annovis Bio, Inc. Annovis Bio Reports $6.2 Million Net Loss in Q2 2025, Increases Total Assets to $21.5 Million

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
Annovis Bio, Inc. Annovis Bio Reports $5.5 Million Net Loss in Q1 2025, Cash Balance Increases to $22.2 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Annovis Bio, Inc. Annovis Bio Reports 44% Reduction in Net Losses for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Annovis Bio, Inc. Annovis Bio Reports Improved Financials, Net Loss Reduction, and Plans for Additional Capital Raising

Via official filing (AI summary) | over 1 year ago | 0 comments